Henrik Lindman

5.3k total citations
121 papers, 3.1k citations indexed

About

Henrik Lindman is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Henrik Lindman has authored 121 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 89 papers in Oncology, 59 papers in Cancer Research and 31 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Henrik Lindman's work include Breast Cancer Treatment Studies (58 papers), Cancer Treatment and Pharmacology (37 papers) and HER2/EGFR in Cancer Research (35 papers). Henrik Lindman is often cited by papers focused on Breast Cancer Treatment Studies (58 papers), Cancer Treatment and Pharmacology (37 papers) and HER2/EGFR in Cancer Research (35 papers). Henrik Lindman collaborates with scholars based in Sweden, Finland and United States. Henrik Lindman's co-authors include Jonas Bergh, Irma Fredriksson, Lars Holmberg, Hanna Fredholm, Jan Frisell, Joachim Feldwisch, Sonja Eaker, Vladimir Tolmachev, Anders Wennborg and Jörgen Carlsson and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Henrik Lindman

114 papers receiving 3.1k citations

Peers

Countries citing papers authored by Henrik Lindman

Since Specialization

Citations

This map shows the geographic impact of Henrik Lindman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Henrik Lindman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Henrik Lindman more than expected).

Fields of papers citing papers by Henrik Lindman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Henrik Lindman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Henrik Lindman. The network helps show where Henrik Lindman may publish in the future.

Co-authorship network of co-authors of Henrik Lindman

This figure shows the co-authorship network connecting the top 25 collaborators of Henrik Lindman. A scholar is included among the top collaborators of Henrik Lindman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Henrik Lindman. Henrik Lindman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	[⁶⁸Ga]Ga-ABY-025 PET in HER2-positive breast cancer: Benefits and pitfalls in staging of axillary disease. 2024 ·Journal of Clinical Oncology ·(unknown), Henrik Lindman, Per Liss, Fredrik Y. Frejd, Joachim Feldwisch, Nikolai C. Brun, Mark Lubberink, Irina Velikyan, Jens Benn Sørensen	1
2	AAV ‐mouse DNase I sustains long‐term DNase I expression in vivo and suppresses breast cancer metastasis 2024 ·FASEB BioAdvances ·(unknown), (unknown), Jessica Cedervall, (unknown), Falk Saupe, (unknown), Henrik Lindman, Casey A. Maguire, George Tetz, Victor Tetz, Anna‐Karin Olsson	3
3	Effects of heavy‐load strength training during (neo‐)adjuvant chemotherapy on muscle strength, muscle fiber size, myonuclei, and satellite cells in women with breast cancer 2024 ·The FASEB Journal ·Olav Vikmoen, (unknown), (unknown), (unknown), (unknown), Birgitta Johansson, (unknown), Andreas Karakatsanis, (unknown), (unknown), Henrik Lindman, (unknown), Sveinung Berntsen, Ingrid Demmelmaier, Karin Nordin, Truls Raastad	3
4	Omission of postoperative radiotherapy after breast-conserving surgery in low-risk breast cancer 2024 ·JNCI Journal of the National Cancer Institute ·(unknown), Antonios Valachis, Henrik Lindman, Daniel R. Smith, (unknown), Fredrika Killander, Judith Bjöhle, (unknown), Greger Nilsson, Johan Ahlgren, Kenneth Villman	0
5	The role of serum thymidine kinase 1 activity in neoadjuvant-treated HER2-positive breast cancer: biomarker analysis from the Swedish phase II randomized PREDIX HER2 trial 2024 ·Breast Cancer Research and Treatment ·(unknown), Ioannis Zerdes, Alexios Matikas, (unknown), Mattias Bergqvist, (unknown), Ana Bosch, Henrik Lindman, (unknown), Anne Andersson, Lena Carlsson, Ann Charlotte Dreifaldt, (unknown), Mats Hellström, Hemming Johansson, Kang Wang, Jonas Bergh, Thomas Hatschek, Theodoros Foukakis	2
6	Long-Term Outcomes of Adjuvant Trastuzumab for 9 Weeks or 1 Year for ERBB2-Positive Breast Cancer 2024 ·JAMA Network Open ·Heikki Joensuu, Judith Fraser, Hans Wildiers, Riikka Huovinen, Päivi Auvinen, Meri Utriainen, Kenneth Villman, Päivi Halonen, (unknown), Minna Tanner, Liisa Sailas, Taina Turpeenniemi‐Hujanen, Jeffrey Yachnin, Teppo Huttunen, Patrick Neven, Peter Canney, Vernon Harvey, Pirkko‐Liisa Kellokumpu‐Lehtinen, Henrik Lindman	0
7	Breast cancer survival and incidence of second primary cancers after 30 years in a randomized study of two versus five years of adjuvant tamoxifen therapy 2023 ·The Breast ·Anna Nordenskjöld, Helena Fohlin, Johan Rosell, Nils‐Olof Bengtsson, Tommy� Fornander, Thomas Hatschek, Henrik Lindman, Per Malmström, Lisa Rydén, Arne Wallgren, Olle Stål, Bo Nordenskjöld	2
8	Long-term treatment patterns and survival in metastatic breast cancer by intrinsic subtypes – an observational cohort study in Sweden 2022 ·BMC Cancer ·Henrik Lindman, Fredrik Wiklund, Klaus Kaae Andersen	15
9	Aromatase inhibitors use and risk for cardiovascular disease in breast cancer patients: A population-based cohort study 2021 ·The Breast ·(unknown), Miguel Garcia‐Argibay, Hans Garmo, Johan Ahlgren, Anna-Karin Wennstig, Irma Fredriksson, Henrik Lindman, Antonios Valachis	28
10	LBA11 Individual patient data meta-analysis of 5 non-inferiority RCTs of reduced duration single agent adjuvant trastuzumab in the treatment of HER2 positive early breast cancer 2021 ·Annals of Oncology ·Helena Earl, Louise Hiller, Julie Dunn, Pierfranco Conté, Roberto D’Amico, Valentina Guarneri, Heikki Joensuu, Teppo Huttunen, (unknown), James Abraham, David Cameron, D.W. Miles, Andrew Wardley, Gilles Romieu, M. Debled, (unknown), Henrik Lindman, Judith Fraser, (unknown), Xavier Pivot	14
11	Predictive Biomarkers for Adjuvant Capecitabine Benefit in Early-Stage Triple-Negative Breast Cancer in the FinXX Clinical Trial 2020 ·Clinical Cancer Research ·Karama Asleh, Heather Ann Brauer, Amy Sullivan, Susanna Lauttia, Henrik Lindman, Torsten O. Nielsen, Heikki Joensuu, E. Aubrey Thompson, Saranya Chumsri	20
12	Cross comparison and prognostic assessment of breast cancer multigene signatures in a large population-based contemporary clinical series 2019 ·Scientific Reports ·Johan Vallon‐Christersson, Jari Häkkinen, Cecilia Hegardt, Lao H. Saal, Christer Larsson, Anna Ehinger, Henrik Lindman, Helena Olofsson, Tobias Sjöblom, Fredrik Wärnberg, Lisa Rydén, Niklas Loman, Martin Malmberg, Åke Borg, Johan Staaf	36
13	Metastatic or locally advanced breast cancer patients: towards an expert consensus on nab-paclitaxel treatment in HER2-negative tumours—the MACBETH project 2018 ·Cancer Chemotherapy and Pharmacology ·(unknown), Marina Elena Cazzaniga, Eva Ciruelos, Alessandra Fabi, José Á. García-Sáenz, Henrik Lindman, D. Mavroudis, Christian Schem, G. Steger, Eleni Timotheadou, Khalil Zaman, Valter Torri	2
14	The risk of febrile neutropenia in breast cancer patients following adjuvant chemotherapy is predicted by the time course of interleukin‐6 and C‐reactive protein by modelling 2017 ·British Journal of Clinical Pharmacology ·(unknown), Mats O. Karlsson, Elisabet I. Nielsen, Angelica Quartino, Henrik Lindman, Lena E. Friberg	11
15	Intra-image referencing for simplified assessment of HER2-expression in breast cancer metastases using the Affibody molecule ABY-025 with PET and SPECT 2017 ·European Journal of Nuclear Medicine and Molecular Imaging ·Dan Sandberg, Vladimir Tolmachev, Irina Velikyan, Helena Olofsson, Anders Wennborg, Joachim Feldwisch, Jörgen Carlsson, Henrik Lindman, Jens Sørensen	44
16	Breast cancer in young women and prognosis: How important are proliferation markers? 2017 ·European Journal of Cancer ·Hanna Fredholm, Kristina Magnusson, Linda S. Lindström, Nicholas P. Tobin, Henrik Lindman, Jonas Bergh, Lars Holmberg, Fredrik Pontén, Jan Frisell, Irma Fredriksson	29
17	GMP compliant preparation of a (68)Gallium-labeled Affibody analogue for breast cancer patient examination : first-in-man 2014 ·European Journal of Nuclear Medicine and Molecular Imaging ·Irina Velikyan, Anders Wennborg, Joachim Feldwisch, Anna Orlova, Vladimir Tolmachev, Mark Lubberink, Mattias Sandström, Henrik Lindman, Jörgen Carlsson, Jens Christian Hedemann Sørensen	3
18	Measuring HER2-expression in metastatic breast cancer using 68Ga-ABY025 PET/CT 2014 ·European Journal of Nuclear Medicine and Molecular Imaging ·Jens Nørkær Sørensen, Irina Velikyan, Anders Wennborg, Joachim Feldwisch, Vladimir Tolmachev, Dan Sandberg, Greger Nilsson, (unknown), Mattias Sandström, Mark Lubberink, Jörgen Carlsson, Henrik Lindman	3
19	Outcome of patients with HER2-positive breast cancer treated with or without adjuvant trastuzumab in the Finland Capecitabine Trial (FinXX) 2013 ·Acta Oncologica ·Heikki Joensuu, Pirkko‐Liisa Kellokumpu‐Lehtinen, Riikka Huovinen, Arja Jukkola‐Vuorinen, Minna Tanner, R. Kokko, Johan Ahlgren, Päivi Auvinen, (unknown), Leena Helle, Kenneth Villman, Paul Nyandoto, Greger Nilsson, Mika Leinonen, Vesa Kataja, Petri Bono, Henrik Lindman	22
20	Test-retest reproducibility of [F-18]fluciclatide PET imaging in subjects with solid tumors 2012 ·European Journal of Nuclear Medicine and Molecular Imaging ·Rakesh Sharma, (unknown), (unknown), (unknown), Henrik Lindman, Norbert Avril, Fergus Gleeson, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), R. Charles Coombes, Eric O. Aboagye	0

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact